International Immunology Advance Access published online on September 28, 2006
International Immunology, doi:10.1093/intimm/dxl094
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Institut fuer Medizinische Mikrobiologie und Krankenhaushygiene, University of Marburg, BMFZ, Hans-Meerweinstrasse, 35043 Marburg, Germany
* To whom correspondence should be addressed. Previously, we have demonstrated that multidrug-resistance-associated protein 1 (Mrp1) represents an activation marker for murine Th1 cells and is constitutively expressed by Th2 cells. Using the inhibitor MK571, we and others also suggested that Mrp1 is necessary for Th cell activation. However, herein, we show that Mrp1-deficient Th cells can be differentiated to a similar extent to Th1 and Th2 cells in vitro and, upon re-stimulation, produce comparable amounts of IL-2, IFN
Received May 16, 2006
Accepted August 24, 2006
Article
Multidrug-resistance-associated protein 1 (Mrp1) is probably not required for murine Th cell activation
Peter Kleemann 1 *, Baerbel Casper 1, Magdalena Huber 1, John D. Schuetz 2, and Michael Lohoff 1
2 Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN, USA
Peter Kleemann, E-mail: kleemann{at}med.uni-marburg.de
![]()
Abstract
and IL-4. Mrp1-deficient mice are equally susceptible than wild-type mice to infection with the protozoan parasite Leishmania major, a well-respected model for in vivo Th1 and Th2 cell differentiation. Intriguingly, MK571 is able to completely block activation of Mrp1-deficient Th cells. Most likely, therefore, the molecule relevant for Th cell activation which is blocked by MK571 is different from Mrp1. While these results are compatible with our previously reported data on Mrp1 expression, they contradict our previous conclusions about Mrp1 function in murine Th1 cells as well as those published in a very recent report in this journal on human Th cells.![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
R. van de Ven, R. Oerlemans, J. W. van der Heijden, G. L. Scheffer, T. D. de Gruijl, G. Jansen, and R. J. Scheper ABC drug transporters and immunity: novel therapeutic targets in autoimmunity and cancer J. Leukoc. Biol., November 1, 2009; 86(5): 1075 - 1087. [Abstract] [Full Text] [PDF] |
||||
